iShares Biotechnology ETF (NASDAQ:IBB) Reaches New 1-Year High – Here’s What Happened

iShares Biotechnology ETF (NASDAQ:IBB) shares hit a new 52-week high during trading on Monday . The stock traded as high as $159.94 and last traded at $158.9910, with a volume of 365029 shares traded. The stock had previously closed at $157.72.

iShares Biotechnology ETF Stock Up 0.7%

The firm’s 50-day moving average price is $148.73 and its two-hundred day moving average price is $135.76.

iShares Biotechnology ETF Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 19th. Shareholders of record on Tuesday, September 16th were paid a dividend of $0.0828 per share. This represents a $0.33 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend was Tuesday, September 16th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IBB. Brighton Jones LLC acquired a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth approximately $201,000. Woodside Wealth Management LLC acquired a new stake in shares of iShares Biotechnology ETF during the 1st quarter valued at $31,000. Apollon Wealth Management LLC increased its stake in shares of iShares Biotechnology ETF by 1.1% in the first quarter. Apollon Wealth Management LLC now owns 8,754 shares of the financial services provider’s stock worth $1,120,000 after acquiring an additional 96 shares during the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of iShares Biotechnology ETF by 5.2% during the first quarter. SBI Securities Co. Ltd. now owns 2,198 shares of the financial services provider’s stock worth $281,000 after acquiring an additional 108 shares in the last quarter. Finally, Larson Financial Group LLC boosted its position in iShares Biotechnology ETF by 8.7% during the first quarter. Larson Financial Group LLC now owns 1,906 shares of the financial services provider’s stock valued at $244,000 after purchasing an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.